MLANA and melanoma: In an exploratory analysis of the phase III trial EORTC 18991, which compared adjuvant pegylated interferon-alpha-2b with surveillance in patients with resected stage III melanoma, the presence of mCTCs was verified using RT-PCR for tyrosinase and Mart-1/Melan-A transcripts.